Table 1.
Clinicopathologic characteristics of study cohort.
| Characteristic | Number (n = 35) |
|---|---|
| Median age at study entry, in years | 50 (36–75) |
| Ethnicity | |
| Chinese | 23 (65.7%) |
| Malay | 9 (25.7%) |
| Indian | 1 (2.9%) |
| Others | 2 (5.7%) |
| Subtype | |
| HR+/HER2- | 18 (51.4%) |
| HER2+ (regardless of HR) | 14 (40.0%) |
| TNBC | 3 (8.6%) |
| Stage | |
| II | 2 (5.7%) |
| III | 3 (8.6%) |
| IV (all relapsed after prior non-metastatic diagnosis) | 30 (85.7%) |
| Number of prior systemic therapies (including non-metastatic) | |
| 0 | 5 (14.3%) |
| 1 or more | 30 (85.7%) |
| Volume of Disease | |
| Low | 10 (28.6%) |
| Moderate | 14 (40.0%) |
| High | 11 (31.4%) |
| Serum CA15-3 levels | |
| Not raised | 15 (42.9%) |
| Raised | 18 (51.4%) |
| Not available | 2 (5.7%) |